Join Annexon Biosciences for an overview of Guillain-Barré Syndrome (GBS), the most common cause of acute neuromuscular paralysis, featuring GBS experts:

• Lisa Butler, Executive Director, GBS|CIDP Foundation International
• Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology, University of Glasgow
• David Cornblath, MD, Professor Emeritus of Neurology, Johns Hopkins University School of Medicine

Key highlights:

• Current treatment landscape and opportunities for new therapies from the patient and clinician perspective
• Targeting C1q in GBS with ANX005, Annexon’s investigational monoclonal antibody designed to inhibit C1q and stop classical complement pathway activation before it starts
• Annexon’s pivotal Phase 3 trial expected to read out in the second quarter of this year
• The GBS market opportunity and Annexon’s commercial approach

A live question and answer will follow the formal presentation.